Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BIVI |
---|---|---|
09:32 ET | 39811 | 3.35 |
09:33 ET | 3894 | 3.37 |
09:35 ET | 60331 | 3.3179 |
09:37 ET | 24390 | 3.3 |
09:39 ET | 14089 | 3.275 |
09:42 ET | 9215 | 3.28 |
09:44 ET | 22866 | 3.258 |
09:46 ET | 35158 | 3.2201 |
09:48 ET | 41319 | 3.26 |
09:50 ET | 16204 | 3.27 |
09:51 ET | 40626 | 3.305 |
09:53 ET | 50252 | 3.34 |
09:55 ET | 19147 | 3.307 |
09:57 ET | 11681 | 3.3201 |
10:00 ET | 17980 | 3.29 |
10:02 ET | 15784 | 3.276 |
10:04 ET | 30187 | 3.27 |
10:06 ET | 36686 | 3.2493 |
10:08 ET | 45564 | 3.3001 |
10:09 ET | 15150 | 3.2886 |
10:11 ET | 11540 | 3.285 |
10:13 ET | 4493 | 3.26 |
10:15 ET | 10715 | 3.2459 |
10:18 ET | 34923 | 3.28 |
10:20 ET | 9833 | 3.2736 |
10:22 ET | 37102 | 3.3 |
10:24 ET | 11987 | 3.2523 |
10:26 ET | 16468 | 3.26 |
10:27 ET | 4958 | 3.28 |
10:29 ET | 6496 | 3.25 |
10:31 ET | 6837 | 3.2396 |
10:33 ET | 4234 | 3.2371 |
10:36 ET | 6392 | 3.24 |
10:38 ET | 4247 | 3.23 |
10:40 ET | 15255 | 3.2025 |
10:42 ET | 8994 | 3.2 |
10:44 ET | 6825 | 3.22 |
10:45 ET | 27146 | 3.21 |
10:47 ET | 32115 | 3.18 |
10:49 ET | 17822 | 3.21 |
10:51 ET | 16951 | 3.2323 |
10:54 ET | 20220 | 3.2 |
10:56 ET | 32276 | 3.21 |
10:58 ET | 2155 | 3.225 |
11:00 ET | 7446 | 3.21 |
11:02 ET | 5722 | 3.21 |
11:03 ET | 5509 | 3.1899 |
11:05 ET | 2484 | 3.2 |
11:07 ET | 1222 | 3.22 |
11:09 ET | 3150 | 3.215 |
11:12 ET | 24658 | 3.18 |
11:14 ET | 10974 | 3.2 |
11:16 ET | 24225 | 3.2099 |
11:18 ET | 23088 | 3.2102 |
11:20 ET | 7305 | 3.22 |
11:21 ET | 73102 | 3.1411 |
11:23 ET | 7405 | 3.1789 |
11:25 ET | 7146 | 3.205 |
11:27 ET | 7055 | 3.215 |
11:30 ET | 7302 | 3.1831 |
11:32 ET | 3902 | 3.2099 |
11:34 ET | 32386 | 3.11 |
11:36 ET | 49909 | 3.11 |
11:38 ET | 87186 | 3.07 |
11:39 ET | 75212 | 3.0411 |
11:41 ET | 87708 | 3.025 |
11:43 ET | 43755 | 3.0011 |
11:45 ET | 55345 | 3.08 |
11:48 ET | 14563 | 3.0492 |
11:50 ET | 44350 | 3.0301 |
11:52 ET | 24682 | 3.08 |
11:54 ET | 12103 | 3.1 |
11:56 ET | 31542 | 3.1 |
11:57 ET | 47008 | 3.1099 |
11:59 ET | 29492 | 3.0928 |
12:01 ET | 20611 | 3.105 |
12:03 ET | 23837 | 3.12 |
12:06 ET | 19719 | 3.12 |
12:08 ET | 2300 | 3.1313 |
12:10 ET | 7602 | 3.1365 |
12:12 ET | 3674 | 3.14 |
12:14 ET | 4999 | 3.12 |
12:15 ET | 7556 | 3.141 |
12:17 ET | 2850 | 3.16 |
12:19 ET | 20223 | 3.1899 |
12:21 ET | 3620 | 3.1885 |
12:24 ET | 57508 | 3.16 |
12:26 ET | 42390 | 3.15 |
12:28 ET | 14270 | 3.12 |
12:30 ET | 4837 | 3.1202 |
12:32 ET | 3150 | 3.1201 |
12:33 ET | 9914 | 3.14 |
12:35 ET | 13560 | 3.1017 |
12:37 ET | 7793 | 3.1071 |
12:39 ET | 8900 | 3.1 |
12:42 ET | 20746 | 3.1005 |
12:44 ET | 6937 | 3.1008 |
12:46 ET | 1547 | 3.1135 |
12:48 ET | 4818 | 3.145 |
12:50 ET | 6900 | 3.13 |
12:51 ET | 1465 | 3.13 |
12:53 ET | 13858 | 3.1498 |
12:55 ET | 7011 | 3.158 |
12:57 ET | 6550 | 3.165 |
01:00 ET | 11292 | 3.1771 |
01:02 ET | 6630 | 3.1709 |
01:04 ET | 4917 | 3.1701 |
01:06 ET | 2260 | 3.1791 |
01:08 ET | 1000 | 3.1799 |
01:09 ET | 9300 | 3.18 |
01:11 ET | 6477 | 3.155 |
01:13 ET | 550 | 3.155 |
01:15 ET | 3000 | 3.1545 |
01:18 ET | 2956 | 3.17 |
01:20 ET | 3700 | 3.185 |
01:22 ET | 7310 | 3.195 |
01:24 ET | 1050 | 3.1911 |
01:26 ET | 9465 | 3.1999 |
01:27 ET | 50386 | 3.235 |
01:29 ET | 5050 | 3.23 |
01:31 ET | 3794 | 3.2409 |
01:33 ET | 12470 | 3.21 |
01:36 ET | 4050 | 3.2091 |
01:38 ET | 3250 | 3.225 |
01:40 ET | 5852 | 3.18 |
01:42 ET | 2395 | 3.2001 |
01:44 ET | 300 | 3.2081 |
01:45 ET | 750 | 3.2 |
01:47 ET | 8719 | 3.181 |
01:49 ET | 1632 | 3.1849 |
01:51 ET | 2100 | 3.208 |
01:54 ET | 17650 | 3.1941 |
01:56 ET | 6297 | 3.205 |
01:58 ET | 2319 | 3.2004 |
02:00 ET | 1683 | 3.199 |
02:02 ET | 800 | 3.1991 |
02:03 ET | 12400 | 3.205 |
02:05 ET | 7977 | 3.195 |
02:07 ET | 8663 | 3.1806 |
02:09 ET | 11712 | 3.1717 |
02:12 ET | 3149 | 3.1595 |
02:14 ET | 20945 | 3.1625 |
02:16 ET | 16538 | 3.1582 |
02:18 ET | 30884 | 3.1909 |
02:20 ET | 5758 | 3.2 |
02:21 ET | 5532 | 3.19 |
02:23 ET | 11897 | 3.1901 |
02:25 ET | 6809 | 3.1901 |
02:27 ET | 3990 | 3.2 |
02:30 ET | 3000 | 3.205 |
02:32 ET | 6610 | 3.21 |
02:34 ET | 2300 | 3.2132 |
02:36 ET | 5066 | 3.2169 |
02:38 ET | 3100 | 3.2145 |
02:39 ET | 1200 | 3.2199 |
02:43 ET | 5055 | 3.2199 |
02:45 ET | 2921 | 3.185 |
02:48 ET | 6091 | 3.1701 |
02:50 ET | 6134 | 3.1899 |
02:52 ET | 7122 | 3.165 |
02:54 ET | 21709 | 3.1878 |
02:56 ET | 5639 | 3.185 |
02:57 ET | 6050 | 3.1697 |
02:59 ET | 500 | 3.165 |
03:01 ET | 2282 | 3.1601 |
03:03 ET | 2735 | 3.165 |
03:06 ET | 19209 | 3.14 |
03:08 ET | 23197 | 3.1395 |
03:10 ET | 24399 | 3.1606 |
03:12 ET | 11093 | 3.1446 |
03:14 ET | 9440 | 3.155 |
03:15 ET | 26338 | 3.175 |
03:17 ET | 1500 | 3.17 |
03:19 ET | 7277 | 3.195 |
03:21 ET | 3570 | 3.19 |
03:24 ET | 4147 | 3.2 |
03:26 ET | 7535 | 3.215 |
03:28 ET | 4650 | 3.215 |
03:30 ET | 4100 | 3.2 |
03:32 ET | 14341 | 3.1801 |
03:33 ET | 2272 | 3.185 |
03:35 ET | 630 | 3.181 |
03:37 ET | 15927 | 3.185 |
03:39 ET | 700 | 3.1899 |
03:42 ET | 1861 | 3.19 |
03:44 ET | 6544 | 3.191183 |
03:46 ET | 3180 | 3.1808 |
03:48 ET | 111073 | 3.11 |
03:50 ET | 2970 | 3.09 |
03:51 ET | 42628 | 3.1099 |
03:53 ET | 25685 | 3.12 |
03:55 ET | 3523 | 3.111183 |
03:57 ET | 14843 | 3.095 |
04:00 ET | 65586 | 3.11 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
BioVie Inc | 55.2M | -0.5x | --- |
Elicio Therapeutics Inc | 55.2M | -1.0x | --- |
Connect Biopharma Holdings Ltd | 54.7M | -2.6x | --- |
Vor Biopharma Inc | 54.7M | -0.5x | --- |
Aileron Therapeutics Inc | 55.9M | -0.8x | --- |
Maia Biotechnology Inc | 54.5M | -1.6x | --- |
BioVie Inc. is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. In neurodegenerative disease, the Company’s drug candidate bezisterim (NE3107) inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated neuroinflammation and insulin resistance but not extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) homeostatic functions (insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is in the phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $55.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 17.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.96 |
EPS | $-5.71 |
Book Value | $2.51 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.